Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling (Q39240972)

10 September 2017

Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling (English)

1 reference

10 September 2017

1 reference

Zi-li Wang

1

1 reference

10 September 2017

Zhi-qiang Fan

series ordinal

2

1 reference

10 September 2017

Han-dong Jiang

series ordinal

3

1 reference

10 September 2017

Jie-ming Qu

series ordinal

4

1 reference

10 September 2017

language of work or name

English

0 references

publication date

21 November 2012

1 reference

10 September 2017

1 reference

10 September 2017

34

1 reference

10 September 2017

638-646

1 reference

10 September 2017

3

1 reference

Transforming growth factor-beta1 increases cell migration and beta1 integrin up-regulation in human lung cancer cells

10 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS367

Lung cancer progression and metastasis from the prognostic point of view.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS367

21 January 2018

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS367

Management and prognosis in synchronous solitary resected brain metastasis from non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS367

Stage IA non-small cell lung cancer: vessel invasion is a poor prognostic factor and a new target of adjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS367

The number of lymph node metastases as a prognostic factor in patients with N1 non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS367

Cyclooxygenases: structural, cellular, and molecular biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS367

Significance of cyclooxygenase-2 in prognosis, targeted therapy and chemoprevention of NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS367

Cyclooxygenase-2 expression is related to the epithelial-to-mesenchymal transition in human colon cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS367

Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS367

Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-beta through a PGE2-dependent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS367

Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS367

Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS367

The role of polymeric immunoglobulin receptor in inflammation-induced tumor metastasis of human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS367

TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS367

Matrix metalloproteinases: regulators of the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS367

Celecoxib antagonizes the cytotoxicity of cisplatin in human esophageal squamous cell carcinoma cells by reducing intracellular cisplatin accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS367

Cyclooxygenase-2 expression during immortalization and breast cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS367

Effects of etodolac, a selective cyclooxygenase-2 inhibitor, on the expression of E-cadherin-catenin complexes in gastrointestinal cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS367

Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS367

Indomethacin induces cellular morphological change and migration via epithelial-mesenchymal transition in A549 human lung cancer cells: a novel cyclooxygenase-inhibition-independent effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS367

The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS367

Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS367

Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS367

Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS367

Celecoxib inhibits cell proliferation through the activation of ERK and p38 MAPK in head and neck squamous cell carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS367

Celecoxib promotes c-FLIP degradation through Akt-independent inhibition of GSK3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS367

Activated PI3K/Akt/COX-2 pathway induces resistance to radiation in human cervical cancer HeLa cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS367

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS367

ERK negatively regulates the epidermal growth factor-mediated interaction of Gab1 and the phosphatidylinositol 3-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS367

Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS367

KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS367

Regulation of Raf-Akt Cross-talk

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS367

21 January 2018

Identifiers

DOI

10.1093/CARCIN/BGS367

1 reference

10 September 2017

1 reference